VECTORS AND METHODS FOR GENETIC IMMUNIZATION
Williams, JA, (2017), US Patent 9,727,630
E. COLI PLASMID DNA PRODUCTION
Williams, JA, Hodgson, CP, Carnes, AE, (2017), US Patent 9,725,725
DNA PLASMIDS WITH IMPROVED EXPRESSION
Williams, JA, (2017), US Patent 9,550,998
Williams, J.A. (2011) US Patent 9,506,082
Williams JA, Carnes AE (2015), US Patent 9,487,788
Williams, JA, Carnes AE (2015), US Patent 9,487,789
VECTORS AND METHOD FOR GENETIC IMMUNIZATION (RNA-OUT ANTIBIOTIC-FREE SELECTABLE MARKER)
Williams, JA (2015), US Patent 9,109,012
Also international filings under Patent Cooperation Treaty, European Patent Application No EP2333091 and EP2152889, Australian Patent No. 2008262478.
Williams, JA (2015), US Patent 9,045,759
Williams, JA (2015), US Patent 9,012,226
Williams, J.A., Hodgson, C.P. (2014): US Patent 8,748,168
Williams, J.A. (2015) US Patent 8,999,672
Carnes, AE, Williams, JA (2011), US 7,943,377
Also international filings under Patent Cooperation Treaty, European Patent No EP1781800, issued 6/19/13 Australian Patent No. 2005277510, and granted patents in Japan, New Zealand, Eurasia, Mexico, India, Israel, Singapore, South Africa.
Hodgson, C.P., Zink, M.A., and Xu, G.,(2000) US Patent 6,573,091
Williams, J.A. (2015) US Application Number 14/748,846
VECTORS AND METHODS FOR GENETIC IMMUNIZATION
Williams, J.A. (2015) US Application Number 14/753,438
Williams, J.A. (2013) PCT/US2013/00067, WO2014/077863
Williams, J.A. (2013) PCT/US2013/00068, WO2014/035457, US2015/0191735
Recent advances in non-viral vectors for gene therapy & vaccination.
Hodgson CP, Carnes AD, Williams JA, (2017) Cell Gene Therapy Insights 3(2):95-101.
A 5’ non-coding exon containing engineered intron enhances transgene expression from recombinant AAV vectors in vivo.
Lu J, Williams JA, Luke J, Zhang, F, Chu K, Kay MA, (2017), Human Gene Therapy, 28:125-134.
A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross reactive humoral and cellular immune responses in pigs.
Borggren M, Nielsen J, Karlsson I, Dalgaard TS, Trebbien R, Williams JA, Fomsgaard A, (2016) Vaccine 34:3634-3640.
Enhanced neutralizing antibody response to Bovine Diarrhoea Virus (BVDV) induced by a DNA vaccine in calves.
El-Attar LM, Thomas C, Luke J, Williams JA, Brownlie J, (2015) Vaccine 33: 4004-4012.
Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans
Borggrena M, Nielsena J, Bragstada K, Karlssona I, Jesper S. Krog JS, Williams JA, Fomsgaardad A DOI:10.1080/21645515.2015.1011987
A Noncytolytic Alpha Toxin Recombinant Protein Protects Turkeys Against Clostridium Septicum Challenge
Lancto CA, Foster LK, Kromm MM, McComb B, Williams JA, Luke J, Carnes A, Hodgson CP, Foster DN, (2014), Avian Diseases 58: 566-571.
Improving DNA Vaccine Performance Through Vector Design
Williams, J.A. (2014) Current Gene Ther. 14:170-189.
Carnes AE, Williams JA, Process for DNA Immunization Applications, in:
Monica Rinaldi et al. (eds.), DNA Vaccines: Methods and Protocols, Methods
in Molecular Biology, vol. 1143, p197-217, Springer Science+Business Media
Luke JM, Carnes AE, Williams JA, Development of Antibiotic-Free Selection
System for Safer DNA Vaccination, in: Monica Rinaldi et al. (eds.), DNA
Vaccines: Methods and Protocols, Methods in Molecular Biology, vol. 1143,
p 91-111, Springer Science+Business Media New York.
Dou C1, Lay F2, Ansari AM2, Rees DJ2, Ahmed AK2, Kovbasnjuk O3, Matsangos AE2, Du J2, Hosseini SM2, Steenbergen C4, Fox-Talbot K4, Tabor AT5, Williams JA6, Liu L2, Marti GP2, Harmon JW2., Mol Ther. 2014 Apr;22(4):752-61. doi: 10.1038/mt.2014.2. Epub 2014 Jan 17.
Antibiotic-free Production of a Herpes Simplex Virus 2 DNA Vaccine in a High Yield cGMP Process.
Jared Nelson, Stephen Rodriguez, Neil Finlayson, Jim Williams and Aaron Carnes, (2013), Human Vaccines & Immunotherapeutics (2013), 9:10, 2211–2215.
Carnes, A.E., Luke, J.M., Vincent, J.M., Schukar, A., Anderson, S., Hodgson, C.P., Williams, J.A. Biotechnol. Bioeng. (2011). Feb;108(2):354-63.
Luke, J.M., Carnes, A.E., Hodgson, C.P., Williams, J.A. Mol. Biotechnol. (2011). 47(1):43-9.
Luke, J.M., Simon, G.G., Soderholm, J., Errett, J.S., August, J.T., Gale, J., Hodgson, C.P., Williams, J.A. (2011). J. Virol. 85:1370-83.
Luke, J., Carnes, A.E., Sun, P., Hodgson, C.P., Waugh, D.S., and Williams, J.A., (2011). J. Biotechnol., 151:242-50.
Luke, J., Vincent, J.M., Du, S.X., Whalen, B., Leen, A., Hodgson, C.P., and Williams, J.A.. Gene Ther.18:334-343 (2011)
Carnes, A.E., Luke, J.M., Vincent, J.M., Anderson, S., Schukar, A, Hodgson, C.P., and Williams, J.A. J. Gene Medicine, (12(10):818-31).
Carnes, AE, Hodgson, CP, Luke, JM, Vincent, JM, Williams, JA, Biotechnol. Bioeng. 104:505-515 (2009)
Williams, JA, Luke, J, Hodgson, CP, Mol. Biotechnol. (2009) 43:41-51
Luke J, Carnes AE, Hodgson CP, Williams JA. Vaccine 27(46):6454-9.(2009)
James A Williams *, Jeremy Luke, Sarah Langtry, Sheryl Anderson, Clague P Hodgson, Aaron E Carnes, Nature Technology Corporation, Lincoln, NE, USA. Biotechnol. Bioeng. (2009) 103:1129-1143
Low Metabolic Burden Plasmid Production
Carnes AE, Williams JA, Gen Eng. Biotech News, (2009) 29:56-57
Williams, J.A., Carnes, A.E., and Hodgson, C.P. (2009). Biotechnology Advances. (2009) 27:35-370
Williams, J.A., Hodgson, C.P., and Carnes, A.E. (2009).BioPharm International 22(11):46-51
Carnes, A., Williams, J., (2007) Current Patents on Biotechnol. 1(2):151-166.C
James A Williams, Jeremy Luke, Lance Johnson, Clague Hodgson, (2006) Vaccine 24:4671-4676
Clague P. Hodgson, Ph.D.
Founder, Chief Executive Officer
Clague Hodgson, NTC’s founder brings 30 years experience in basic and applied genetics research and lab management. Clague previously held faculty positions at Creighton University School of Medicine and The Ohio State University. He was trained at the University of Minnesota (undergraduate and graduate), and at the Mayo Graduate School of Medicine (Ph.D.), with postdoctoral training at Baylor College of Medicine. He has published numerous scientific articles, book chapters, patents, and a book on gene therapy.
Jim Williams, Ph.D.
Chief Scientific Officer
Vice President for Research and Development
Jim Williams, Ph.D., Joined NTC as Lead Scientist and VP, Research and Development, in August, 2002. Jim’s expertise includes regulatory affairs, quality, molecular genetics, fermentation, and protein expression systems. Jim previously held key management and scientific positions at Restoragen (1997-2002) and at Ophidian Pharmaceuticals. Jim received his Ph.D. in genetics (University of Alberta), and completed postdoctoral training at the University of Wisconsin.
Aaron Carnes, B.Sc.Ch.
Director Process Development
Aaron Carnes is a chemical engineer focusing on process development in the fields of fermentation and purification for high yield DNA production. Aaron has worked at NTC for ten years and is a graduate of the University of Nebraska at Lincoln.
Colleen S. Nygren
Treasurer, financial services
Colleen Nygren is a graduate of the University of Nebraska School of Business. Colleen has worked in the accounting field for 20 years, with experience in brokerage, banking, and investment operations.
Computer Graphics and Web Designer
Kris Hodgson is a co-founder of NTC and manages company websites, marketing, advertising, artwork, and electronic publications.
Clague P. Hodgson, Ph.D.
President, CEO Nature Technology Corp.
NTC’s founder has worked full time for the company since March, 1998. Clague previously held faculty positions at Creighton University School of Medicine (Chief, Div. of Cancer Biology, and Associate Professor of Biomedical Sciences, 1991-1998), and The Ohio State University (Assistant Professor, Labs of Molecular and Developmental Biology, 1985-1991). He was trained at the University of Minnesota (undergraduate and graduate), and at the Mayo Graduate School of Medicine (Ph.D., 1983), and completed postdoctoral training at Baylor College of Medicine (1983-1985). He has published numerous scientific articles, book chapters, patents, and a book on gene therapy.
Served as President and CEO of Harris Labs, presently MDS Pharma
Ron has served as president of Harris Laboratories from 1974-1994, and chairman of the board until his retirement in 2000. He was President of the American Council of Independent Laboratories Assurance Company from 1983-1986. Ron is currently President of the Union Internationale des Labortatories Independants. He remains active in the community and has been past president of various civic and professional organizations. He is a current board member of Brian/LGH Medical Center, HDR, Inc. and Woodmen Accicent and Life Incurance Company (Lincoln Insurance Group). Ron has a bachelor's degree in business and an MBA from the University of Nebraska, Lincoln, NE.
Vice President-Private Client Group-RBC Wealth Management
Mr. Kenney is Vice President, Private Client Group, RBC Wealth Management. Prior to his current position he spent four years in the Institutional Investments division of US Bancorp Investments. He is a founder of two companies.
Vice President Supertel Hospitality Inc.
Connie is Vice President, Finance and Accounting at Supertel Hospitality, Inc, a publicly traded hospitality REIT. Connie previously held the positions of VP of Administration and Treasurer of innowave Incorporated (a Mutual of Omaha subsidiary). Prior to innowave, she was a full time member of the Mutual of Omaha mergers and acquisitions team. Connie was an auditor with Coopers and Lybrand for three years prior to working with Mutual of Omaha
Chief Information Officer, and Co- founder of NTC.
Kris handles information technology, art, advertising and publishing at NTC. She also manages the NATX.com and affiliated websites.
Nature Technology Corporation is a biotechnology company that provides industry partners with world class technology platforms including safe and efficacious non-viral vectors (plasmids) and processes for gene therapy and DNA vaccination vector production. NTC also provides cost effective outsourcing of product development services including synthetic gene design, vector construction, plasmid DNA manufacturing and recombinant proteins.
Nature Technology Corporation does not currently have an SEC registered investment opportunity. The company is interested in acquiring and/or consolidating with complimentary front-runners in the fields of gene based medicines (gene therapy and DNA vaccines). As such, corporate and private equity partnering/financing inquiries are invited.
Clague Hodgson, Ph.D., CEO
Mammalian Expression Vectors
Antibiotic Free Vectors
Rig-I Activating Vectors
pVEX™- E. coli Expression Vector
Autolytic E. coli Cell Lines
HyperGRO™, E. coli Cell paste
Contract Plasmid Manufacturing
Small Scale Large Scale
Rapid VACC™ Precision Cloning
Plasmid Detox Services
Vector Retrofit Services
Swap Marker or Promoter
E. coli Genomic DNA Testing
Residual RNA qPCR
Residual RNA gel
Lymulus Endotoxin Testing
Thermostable Protein Expression
HYPERTAQ™ DNA Polymerase
Custom Recombinant Proteins